Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure
Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure
复制标题
DOI：
10.3324/haematol.2012.066217
复制
发表时间：
2013-06-01
期刊：
影响因子：
10.1
通讯作者：
Nakao, Shinji
中科院分区：
文献类型：
--
作者：
Seiki, Yu;Sasaki, Yumi;Nakao, Shinji
虽然骨髓增生异常综合征是一种异质性疾病，包括骨髓衰竭的良性子集类似于再生障碍性贫血，没有实验室检查已经建立，以区分它与骨髓衰竭，可以演变成急性髓性白血病。对120例骨髓增生异常综合征伴血小板减少症（< 100 × 10（9）/L）患者的血浆血小板生成素水平进行了测定，以确定与免疫病理生理学和预后相关的标记物的任何相关性。难治性贫血伴原始细胞过多患者的血小板生成素水平始终较低，而其他骨髓增生异常综合征亚群患者的结果差异更大。血小板生成素水平为320 pg/mL及以上的患者，糖基磷脂酰肌醇锚定蛋白缺陷血细胞增加（49.1%对0%），更可能有低的国际预后评分系统（IPSS）评分（
Although myelodysplastic syndromes are heterogeneous disorders comprising a benign subset of bone marrow failure similar to aplastic anemia, no laboratory test has been established to distinguish it from bone marrow failures that can evolve into acute myeloid leukemia. Plasma thrombopoietin levels were measured in 120 patients who had myelodysplastic syndrome with thrombocytopenia (< 100 x 10(9)/L) to determine any correlation to markers associated with immune pathophysiology and outcome. Thrombopoietin levels were consistently low for patients with refractory anemia with excess of blasts, while patients with other myelodysplatic syndrome subsets had more variable results. Patients with thrombopoietin levels of 320 pg/mL and over had increased glycosylphosphatidylinositol-anchored protein-deficient blood cells (49.1% vs. 0%), were more likely to have a low International Prognostic Scoring System (IPSS) score (